clinical trial · NCT07034768
A Study to Evaluate EDG-7500 in People With Renal Impairment
Renal ImpairmentsEDG-7500
brief summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
started
Jul 22, 2025
primary completion
Dec 22, 2025
completion
Dec 26, 2025
last updated
Mar 12, 2026
official title
A Phase 1, 2-Part, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol